Global overview of injecting drug use and HIV infection among injecting drug users

AIDS ◽  
2004 ◽  
Vol 18 (17) ◽  
pp. 2295-2303 ◽  
Author(s):  
Carmen Aceijas ◽  
Gerry V Stimson ◽  
Matthew Hickman ◽  
Tim Rhodes
2010 ◽  
Vol 16 (2) ◽  
pp. 119 ◽  
Author(s):  
Christine Tindal ◽  
Kay Cook ◽  
Nena Foster

This paper examines the stigma of injecting drug use as an underlying factor in the poor health status of Australian injecting drug users. Drawing on various models of stigma described in the literature, we examine injecting drug users’ experiences. As a case study, examples from Victorian (specifically Melbourne) policy and practice are included to exemplify community and societal attitudes towards injecting drug users and the implications of these for injecting drug user health. We conclude that redressing the negative effects of stigma requires political will, financial support, increased community commitment and a better understanding of the links between the social determinant of health and the poor health status of injecting drug users. Without reducing the stigma of injecting drug use the health of this marginalised population is likely to get worse, which will have broader negative population health effects.


Author(s):  
V. Novikov ◽  
D. Khritinin

The clinical forms and manifestations of neurotic disorders observed in HIV-infected individuals, their syndrome structure is considered in this article. It is found that drug use contributes to the early comorbidity of neurotic disorders due to personality, exogenous and organic impairments caused by HIV infection.


2020 ◽  
Vol 10 (4) ◽  
pp. 775-781
Author(s):  
L. V. Puzyreva ◽  
A. V. Mordyk ◽  
M. A. Paneva

Bacterial pneumonia holds the second place after respiratory tuberculosis in patients with HIV infection. In recent years, sexual transmission of HIV was replaced by injection drug route. It seems of high relevance to advance medical aid to patients with HIV infection and bacterial pneumonia depending on psychoactive substance use.Aim of study — assessment of clinical and immunological manifestations of bacterial pneumonia coupled to HIV infection with respect to verified injection drug use.Materials and methods. Clinical and immunological data collected from 224 patients with HIV infection and pneumonia were retrospectively analyzed: group 1 group — 70 patients with HIV infection, IDU, verified bacterial pneumonia; group 2 — 16 injecting drug users (IDU) with HIV infection and pneumonia of unverified etiology; group 3 — 65 patients with HIV and bacterial pneumonia of verified etiology without injection drug use, group 4 — 73 patients with HIV infection and bacterial pneumonia of unverified etiology, without injection drug use. The data obtained were analyzed by using software Statistica 13.3. Methods of descriptive statistics with calculation of nonparametric criterion — the Kruskall—Wallis test (H-criterion) and χ2 test — were used.Results. Immunological manifestations of HIV infection and bacterial pneumonia were characterized by decreased count of CD4+ cells paralleled with increased count of CD3+ and CD8+ cells at higher magnitude without injection drug use being also featured with peak viral load upon developing pneumonia. Bacterial pneumonia coupled to HIV infection showed clinical manifestations similar both in injecting drug users and non-users, proceeding in 10% cases during normothermia. Injection drug user patients often demonstrated clinical picture of pneumonia resembling those found in sepsis such as pain in the body, muscles, bone aches untypical to HIV-sexually infected subjects. In addition, systolic murmur on a heart top was more often auscultated in this patient group.Conclusion. Subjects self-considered healthy being at risk of sexually transmitted infections should examined for HIV. All subjects manifested with symptoms of the lower airway tract infections in admission department should not be rejected to be hospitalized and undergo chest X-ray examination.


2020 ◽  
Author(s):  
Gabriel O Dida ◽  
Francis Oguya ◽  
Patrick Kenya ◽  
Francisca Ongecha ◽  
Patrick Mureithi ◽  
...  

Abstract Background: A Cross-sectional Rapid Situational Assessment of Injecting Drug Users (IDUs) applying Respondent Driven sampling techniques (RDS) was used to recruit subjects/participants in a study aimed at assessing HIV prevalence and risk behaviors among injection drug users in Nairobi and Mombasa counties of Kenya. The study sought to establish HIV prevalence and document risk behaviors among IDUs in the two regions, as well as assess their spatial distribution and size estimates in the general population. Methods: A cross-sectional study design was adopted in which a set of initial subjects referred to as ‘seeds’ were first identified from which an expanding chain of referrals was obtained, with subjects from each wave referring subjects of subsequent wave. The seeds were drawn randomly from the population and interviewed to pick the one with the largest network and other unique characteristics. A maximum of twelve seeds were recruited. The second stage involved conducting assessment visits to the sites to identify potential collaborators that included non-governmental organizations (NGOs), drug treatment centres, health facilities, Community based organizations (CBO's), among others. Three NGOs located in the Mombasa county and one in Nairobi county were identified to assist in identifying drug injection locations and potential participants. Key informant interviews (KIIs) and Focus Group Discussions (FGDs) were also conducted using interview guides. Results: A total of 646 individuals (344 in Nairobi and 302 at the coast) were recruited for the study between January and March 2010. Of these 590 (91%) were males and 56 (9%) were female. Findings showed that most IDUs initiated injecting drug use between the ages of 20-29 years, with the youngest age of initiation being 11 years and oldest age being 53 years. Most commonly injected drug was heroin (98%), with a small (2%) percentage injecting cocaine. Other non-injecting methods such as smoking or combining these two drugs with other drugs such as cannabis or rohypnol were also common. Most IDUs used other substances (cigarettes, alcohol, and cannabis) before initiating injecting drug use. While all IDUs continue to be at risk in the two regions, those from the Western parts of Nairobi were at a relatively higher risk given their higher rate of sharing injecting equipment and solutions. Conclusions: Given that initiation of injection drug use begins early and peaks mainly after formal school years (20-29 years), preventive programmes should be targeted at secondary school, college and out of school youth. Further, to protect People who inject drugs (PWIDs) from HIV infection, the country should introduce free Needle Syringe Programs with provision of condoms and Methadone Assisted Therapy as a substitute for drug use.


2006 ◽  
Vol 11 (4) ◽  
pp. 11-12 ◽  
Author(s):  
M Rosinska

The first HIV/ AIDS cases in Poland were diagnosed in the mid-1980, and the outbreak in injecting drug users was first observed in 1989. For many years the HIV epidemic in Poland was driven by injecting drug use. In this study we examine the trends in the HIV/ AIDS epidemic based on the surveillance data for 1999-2004. During this period, 3561 new HIV infections (annual rate of 15.4 per 1 000 000 inhabitants) were reported and 803 incident AIDS cases (incidence 3.5 per 1 000 000) were diagnosed. Both the annual number of newly detected HIV infections and the AIDS incidence showed a slight increasing trend. In particular, the vertically transmitted AIDS incidence increased from 0.46 in 1999 - 2000 to 0.91 per 1 000 000 children under 15 years in 2003 - 2004. Approximately 36% of AIDS patients aged 15 years or above had not been previously diagnosed with HIV. The annual number of the late presenters increased markedly between 1999 and 2004 and was higher amongst individuals infected through sexual transmission (51.0%) than those infected by injecting drug use (20.1%) . Injecting drug users made up 78.6% of new HIV infections with known transmission route, but for 47.9% of all cases the route of transmission was not reported. In order to generate more accurate data, HIV surveillance must be enhanced. Nevertheless, there is clear evidence for implementation of a comprehensive programme of prevention of vertical transmission and encouraging more extensive HIV testing especially in the groups at risk for sexual transmission. An effort is needed to enhance HIV surveillance and prevention in the framework of programmes for STI.


Sign in / Sign up

Export Citation Format

Share Document